270 related articles for article (PubMed ID: 33725402)
1. A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.
Wada Y; Shimada M; Yamamura K; Toshima T; Banwait JK; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Hepatology; 2021 Sep; 74(3):1371-1383. PubMed ID: 33725402
[TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma.
Sulpice L; Rayar M; Turlin B; Boucher E; Bellaud P; Desille M; Meunier B; Clément B; Boudjema K; Coulouarn C
J Surg Res; 2014 Nov; 192(1):117-23. PubMed ID: 24909871
[TBL] [Abstract][Full Text] [Related]
3. EMLI-ICC: an ensemble machine learning-based integration algorithm for metastasis prediction and risk stratification in intrahepatic cholangiocarcinoma.
Ruan J; Xu S; Chen R; Qu W; Li Q; Ye C; Wu W; Jiang Q; Yan F; Shen E; Chu Q; Jia Y; Zhang X; Fu W; Chen J; Timko MP; Zhao P; Fan L; Shen Y
Brief Bioinform; 2022 Nov; 23(6):. PubMed ID: 36259363
[TBL] [Abstract][Full Text] [Related]
4. A blood-based noninvasive miRNA signature for predicting survival outcomes in patients with intrahepatic cholangiocarcinoma.
Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Br J Cancer; 2022 May; 126(8):1196-1204. PubMed ID: 35079106
[TBL] [Abstract][Full Text] [Related]
5. A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.
Wada Y; Shimada M; Morine Y; Ikemoto T; Saito Y; Baba H; Mori M; Goel A
Eur J Cancer; 2022 Mar; 163():66-76. PubMed ID: 35042069
[TBL] [Abstract][Full Text] [Related]
6. Downregulated Expression of Tropomyosin 1 in Intrahepatic Cholangiocarcinoma: A Predictor of Recurrence and Prognosis.
Chen Y; Hong Z; Lu S; Zhang N; Rong G; Chang X; Liu Z; Bai W; Dong Z; Gao X; Zeng Z; Lu Y
Med Sci Monit; 2018 Nov; 24():7875-7882. PubMed ID: 30390420
[TBL] [Abstract][Full Text] [Related]
7. Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer.
Lee IS; Sahu D; Hur H; Yook JH; Kim BS; Goel A
Gastric Cancer; 2021 May; 24(3):655-665. PubMed ID: 33523340
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a plasma metabolomics-based model for risk stratification of intrahepatic cholangiocarcinoma.
Tan J; Shu M; Liao J; Liang R; Liu S; Kuang M; Peng S; Xiao H; Zhou Q
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12365-12377. PubMed ID: 37436513
[TBL] [Abstract][Full Text] [Related]
9. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
Zhou SL; Xin HY; Sun RQ; Zhou ZJ; Hu ZQ; Luo CB; Wang PC; Li J; Fan J; Zhou J
JAMA Surg; 2022 Jan; 157(1):59-65. PubMed ID: 34730772
[TBL] [Abstract][Full Text] [Related]
10. Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma.
Yu WL; Yu G; Dong H; Chen K; Xie J; Yu H; Ji Y; Yang GS; Li AJ; Cong WM; Jin GZ
J Gastroenterol; 2020 Dec; 55(12):1171-1182. PubMed ID: 33089343
[TBL] [Abstract][Full Text] [Related]
11. Establishment and characterisation of six human biliary tract cancer cell lines.
Ku JL; Yoon KA; Kim IJ; Kim WH; Jang JY; Suh KS; Kim SW; Park YH; Hwang JH; Yoon YB; Park JG
Br J Cancer; 2002 Jul; 87(2):187-93. PubMed ID: 12107841
[TBL] [Abstract][Full Text] [Related]
12. Early Onset Intrahepatic Cholangiocarcinoma: Clinical Characteristics, Oncological Outcomes, and Genomic/Transcriptomic Features.
Tsilimigras DI; Han X; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Chaucy F; Koerkamp BG; Endo I; Sasaki K; Aucejo F; Zhang XF; Zhu H; Pawlik TM
Ann Surg Oncol; 2024 May; 31(5):3087-3097. PubMed ID: 38347332
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
14. A novel five-lncRNA signature panel improves high-risk survival prediction in patients with cholangiocarcinoma.
Xie X; Wang Y; Zhang S; Li J; Yu Z; Ding X; Ye L; Gong P; Zhu Q; Li J; Chen Z; Yao X; Du Z; Zeng Q; Chen H; Yang Z; Chen G
Aging (Albany NY); 2021 Jan; 13(2):2959-2981. PubMed ID: 33472169
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
16. Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis.
Zhang MY; Li SH; Huang GL; Lin GH; Shuang ZY; Lao XM; Xu L; Lin XJ; Wang HY; Li SP
BMC Cancer; 2015 Feb; 15():64. PubMed ID: 25880914
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
Zhu AX; Borger DR; Kim Y; Cosgrove D; Ejaz A; Alexandrescu S; Groeschl RT; Deshpande V; Lindberg JM; Ferrone C; Sempoux C; Yau T; Poon R; Popescu I; Bauer TW; Gamblin TC; Gigot JF; Anders RA; Pawlik TM
Ann Surg Oncol; 2014 Nov; 21(12):3827-34. PubMed ID: 24889489
[TBL] [Abstract][Full Text] [Related]
18. An integrated mRNA-lncRNA signature for overall survival prediction in cholangiocarcinoma.
Xu D; Wei L; Zeng L; Mukiibi R; Xin H; Zhang F
Medicine (Baltimore); 2023 Sep; 102(39):e35348. PubMed ID: 37773863
[TBL] [Abstract][Full Text] [Related]
19. Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma.
Bergeat D; Fautrel A; Turlin B; Merdrignac A; Rayar M; Boudjema K; Coulouarn C; Sulpice L
J Surg Res; 2016 Jun; 203(2):441-50. PubMed ID: 27363654
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinoma.
Nishiwada S; Cui Y; Sho M; Jun E; Akahori T; Nakamura K; Sonohara F; Yamada S; Fujii T; Han IW; Tsai S; Kodera Y; Park JO; Von Hoff D; Kim SC; Li W; Goel A
Ann Surg; 2022 Dec; 276(6):e876-e885. PubMed ID: 34132691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
